TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma expressing guanylyl cyclase C (GCC). Materials and Methods Adult patients with advanced GI malignancies expressing GCC (H-score 10) received TAK-264 on day 1 of 3-week cycles as 30-minute intravenous infusions for up to 1 year or until disease progression or unacceptable toxicity. The primary objectives were to evaluate the safety profile including dose-limiting toxicities (DLTs) during cycle 1, determine the maximum tolerated dose (MTD), and characterize the PK profile of TAK-264. Results Twelve patients were enrolled and treated with 1.2 mg/kg (n=3), 1.5 mg/kg (n=3), or 1.8 mg/kg TAK-264 (n=6). Median number of treatment cycles received was two (range, 1 to 10). None of the patients experienced a DLT and the MTD was not determined. Ten patients (83%) experienced adverse events (AEs). The most common were neutropenia, anorexia, and nausea (each reported by four patients). Five patients (42%) experienced grade 3 AEs consisting of tumor hemorrhage and hypertension, ascites, adrenal insufficiency, neutropenia and asthenia. Serum exposure to TAK-264 increased proportionally with the dose and the median half-life was approximately 5.5-6.6 days. No patients experienced an objective response. Conclusion TAK-264 demonstrated a manageable safety profile with limited antitumor activity consistent with studies conducted in Western patients with advanced GI malignancies. TAK-264 exposure increased proportionally with the dose.
Abstract
Purpose This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma expressing guanylyl cyclase C (GCC). Materials and Methods Adult patients with advanced GI malignancies expressing GCC (H-score 10) received TAK-264 on day 1 of 3-week cycles as 30-minute intravenous infusions for up to 1 year or until disease progression or unacceptable toxicity. The primary objectives were to evaluate the safety profile including dose-limiting toxicities (DLTs) during cycle 1, determine the maximum tolerated dose (MTD), and characterize the PK profile of TAK-264. Results Twelve patients were enrolled and treated with 1.2 mg/kg (n=3), 1.5 mg/kg (n=3), or 1.8 mg/kg TAK-264 (n=6). Median number of treatment cycles received was two (range, 1 to 10). None of the patients experienced a DLT and the MTD was not determined. Ten patients (83%) experienced adverse events (AEs). The most common were neutropenia, anorexia, and nausea (each reported by four patients). Five patients (42%) experienced grade 3 AEs consisting of tumor hemorrhage and hypertension, ascites, adrenal insufficiency, neutropenia and asthenia. Serum exposure to TAK-264 increased proportionally with the dose and the median half-life was approximately 5.5-6.6 days. No patients experienced an objective response. Conclusion TAK-264 demonstrated a manageable safety profile with limited antitumor activity consistent with studies conducted in Western patients with advanced GI malignancies. TAK-264 exposure increased proportionally with the dose.
참고문헌 (31)
- Teicher BA, "Antibody conjugate therapeutics: challenges and potential", Clin Cancer Res, 17, pp.6389~6397 (2011)[DOI]
- Panowski S, "Site-specific antibody drug conjugates for cancer therapy", MAbs, 6, pp.34~45 (2014)[DOI]
- Chen R, "Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma", Blood, 128, pp.1562~1566 (2016)[DOI]
- Van den Mooter T, "Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer", Expert Opin Biol Ther, 15, pp.749~760 (2015)[DOI]
- Tsuchikama K, "Antibody-drug conjugates: recent advances in conjugation and linker chemistries", Protein Cell (2016)[DOI]
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)[DOI]
- Koizumi W, "Chemotherapy for advanced gastric cancer: review of global and Japanese status", Gastrointest Cancer Res, 1, pp.197~203 (2007)
- Aesun Shin, "Gastric Cancer Epidemiology in Korea", Journal of Gastric Cancer, 11(3), pp.135~140 (2011), 대한위암학회
- Kanagavel D, "Second-line treatment of metastatic gastric cancer: Current options and future directions", World J Gastroenterol, 21, pp.11621~11635 (2015)[DOI]
- Carrithers SL, "Escherichia coli heat-stable enterotoxin receptors: a novel marker for colorectal tumors", Dis Colon Rectum, 39, pp.171~181 (1996)[DOI]
- Hyslop T, "Guanylyl cyclase C as a biomarker in colorectal cancer", Biomark Med, 7, pp.159~167 (2013)[DOI]
- Li P, "Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity", Gastroenterology, 133, pp.599~607 (2007)[DOI]
- Vaandrager AB, "Structure and function of the heat-stable enterotoxin receptor", guanylyl cyclase C, 2002, pp.230, 73~83
- John M, "Guanylin stimulates regulated secretion from human neuroendocrine pancreatic cells", Gastroenterology, 114, pp.791~797 (1998)[DOI]
- Kloeters O, "Uroguanylin inhibits proliferation of pancreatic cancer cells", Scand J Gastroenterol, 43, pp.447~455 (2008)[DOI]
- Park J, "Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach", Cancer Epidemiol Biomarkers Prev, 11, pp.739~744 (2002)
- Carrithers SL, "Escherichia coli heat-stable toxin receptors in human colonic tumors", Gastroenterology, 107, pp.1653~1661 (1994)[DOI]
- Buc E, "Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells", Eur J Cancer, 41, pp.1618~1627 (2005)[DOI]
- Camci C, "Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients", Tumour Biol, 32, pp.1265~1270 (2011)[DOI]
- Winn B, "Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas", Hum Pathol, 41, pp.123~128 (2010)[DOI]
- Wolfe HR, "In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand", J Nucl Med, 43, pp.392~399 (2002)
- Almhanna K, "Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies", Clin Cancer Res, 22, pp.5049~5057 (2016)[DOI]
- Peters C, "Antibody-drug conjugates as novel anticancer chemotherapeutics", Biosci Rep, 35, pp.e00225~ (2015)[DOI]
- van Diest PJ, "A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group", J Clin Pathol, 50, pp.801~804 (1997)[DOI]
- Younes A, "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma", J Clin Oncol, 30, pp.2183~2189 (2012)[DOI]
- Pro B, "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study", J Clin Oncol, 30, pp.2190~2196 (2012)[DOI]
- Morschhauser F, "Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed", refractory non-Hodgkin lymphoma, 2014, pp.124, 4457~
- Almhanna K, "Phase 2 trial of TAK-264 (MLN0264) in previously-treated patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C", AACR Annual Meeting 2016 (2016), American Association for Cancer Research
- Diamantis N, "Antibody-drug conjugates: an emerging class of cancer treatment", Br J Cancer, 114, pp.362~367 (2016)[DOI]
- Garcia-Echeverria C, "Developing second generation antibody-drug conjugates: the quest for new technologies", J Med Chem, 57, pp.7888~7889 (2014)[DOI]
- Junutula JR, "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index", Nat Biotechnol, 26, pp.925~932 (2008)[DOI]